A non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia, and Tanzania:a CUTTS HepC study protocol
Rattachement africain : au, be, pk, ca, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Despite the availability of curative treatments, hepatitis C diagnosis and treatment coverage is sub-optimal globally with few countries on track to achieve the World Health Organization's 2030 elimination targets. In 2022, an estimated 50 million people were living with hepatitis C with one million new infections annually. Most people living with hepatitis C reside in low-and middle-income countries, and people who inject drugs are disproportionately affected by hepatitis C. Continuing simplification of diagnostic pathways and treatment care models is required to improve linkage to care and reduce costs associated with hepatitis C treatment and cure. Methods and Analysis: This study is a multi-country non-randomised, quasi-experimental, prospective comparative two-arm trial. It aims to assess the feasibility of implementation, retention in hepatitis C care and achievement of cure and cost-effectiveness outcomes, comparing two simplified hepatitis C testing and treatment pathways. Arm 1 is a standard simplified test and treat model of care following global guidance, and Arm 2 is an innovative rapid, same-day treatment initiation model of care using a presumptive treatment approach based on shortened-read time of the point-of-care OraQuick® hepatitis C antibody test result. Secondary outcomes include assessing the accuracy of the OraQuick hepatitis C antibody test in predicting viremia and the acceptability of each pathway. This study will be implemented in Armenia, Georgia and Tanzania. Treatment naive people who inject drugs aged over 18 years in each country will be eligible for enrolment. Recruitment commenced October 2024 in Armenia, June 2025 in Georgia and August 2025 in Tanzania and is anticipated to close by December 2026. Ethics and Dissemination: This trial has been reviewed by WHO ERC, Alfred Hospital Ethics Committee (Australia), and local country ERC’s. Alongside journal publications and conferences, the results from this study will be disseminated through summary reports and workshops with key stakeholders and with communities of people affected by HCV through relevant organisations / networks, including the global Community Advisory Board. The study results will inform national scale-up of simplified care models and inform potential pathways for further simplification of care models, including the potential for one-step diagnostic pathways and same-day treatment in particular scenarios for the three study countries, and other low and middle-income countries globally. Trial registration: This trial is registered at https://clinicaltrials.gov/ . Trial was registered on 6 December 2023, NCT06159504.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
Où se fait cette recherche
-
Burnet Institute pays non établi dans la noticeOrganisation à but non lucratif
-
Australian Regenerative Medicine Institute pays non établi dans la noticeStructure de recherche
-
Monash University pays non établi dans la noticeUniversité ou école supérieure
-
Médecins du Monde pays non établi dans la noticeÉtablissement de santé
-
World Health Organization - Pakistan pays non établi dans la noticeOrganisme public
-
Institute of Infection and Immunity pays non établi dans la noticeStructure de recherche
-
Cabot (United States) pays non établi dans la noticeEntreprise
-
La Trobe University pays non établi dans la noticeUniversité ou école supérieure
-
The University of Melbourne pays non établi dans la noticeUniversité ou école supérieure
-
The Alfred Hospital pays non établi dans la noticeÉtablissement de santé
-
Peter Doherty Institute pays non établi dans la noticeStructure de recherche
-
WHO pays non établi dans la noticeInstitution
Burnet Institute, Australian Regenerative Medicine Institute et Monash University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.